As mag­ni­tude and fre­quen­cy of drug price hikes thaw, Ex­press Scripts re­ports low­est in­crease in spend­ing by com­mer­cial plans in 25 years

In an era where drug­mak­ers and pre­scrip­tion drug man­agers (PBMs) point fin­gers at each oth­er when it comes to jus­ti­fy­ing the rea­sons be­hind ris­ing drug prices — the largest US PBM, Ex­press Scripts, on Wednes­day re­leased a re­port in­di­cat­ing that in 2018 em­ploy­er-spon­sored plans paid rough­ly 6 cents more, on av­er­age, for a 30-day pre­scrip­tion (0.4% hike) ver­sus the pre­ced­ing year, mark­ing the small­est in­crease in com­mer­cial plans in a quar­ter cen­tu­ry.

The com­pa­ny an­a­lyzed pre­scrip­tion drug use da­ta of rough­ly 34.2 mil­lion mem­bers with a phar­ma­cy ben­e­fit plan and cal­cu­lat­ed that it had saved its mem­bers $45 bil­lion in pre­scrip­tion drug costs in 2018.

Al­though spend­ing on tra­di­tion­al, non-spe­cial­ty med­ica­tions dipped 5.8%, spend­ing on spe­cial­ty med­ica­tions rose 9.4%, Ex­press Scripts said. Drugs for in­flam­ma­to­ry con­di­tions such as rheuma­toid arthri­tis and Crohn’s dis­ease ac­count­ed for the costli­est ther­a­py class for the third con­sec­u­tive year, cost­ing em­ploy­ers $174.45 per mem­ber per year in 2018, up 14% from 2017, it added. Glob­al­ly, Ab­b­Vie’s in­flam­ma­to­ry drug Hu­mi­ra — the world’s best-sell­ing med­i­cine — gen­er­at­ed near­ly $20 bil­lion in 2018 sales.

Di­a­betes was the sec­ond costli­est ther­a­py class for em­ploy­ers at $114.85 per mem­ber per year, an in­crease of 4.1% over 2017, the com­pa­ny said, adding that spend­ing on in­sulin, which ac­counts for 15.3% of di­a­betes pre­scrip­tions, rose 0.3% in 2018 (a 1.5% de­cline in unit costs and a 1.8% rise in uti­liza­tion). Anec­do­tal re­ports of di­a­bet­ics ra­tioning or for­go­ing life-sav­ing in­sulin in the Unit­ed States are on the rise.

For a long time drug­mak­ers jus­ti­fied their pol­i­cy of sus­tained drug price hikes on the heavy cost of in­no­va­tion. How­ev­er, as PBMs in­creas­ing­ly threat­en to ex­clude treat­ments from for­mu­la­ries — un­less they man­age to ne­go­ti­ate a dis­count sat­is­fac­to­ry to their de­mands — drug­mak­ers in re­sponse have boost­ed re­bates, and in turn hiked prices in or­der to main­tain their cut of sales.

De­spite list price in­fla­tion of 7.3% for the most com­mon­ly used tra­di­tion­al brand med­ica­tions in 2018, costs for such drugs dipped 6.5% for its em­ploy­er-spon­sored plans, Ex­press Scripts said.

The com­pa­ny has dri­ven a 0.4% de­cline in drug unit costs by steer­ing mem­bers to low­er cost ther­a­pies, and by se­cur­ing deep­er dis­counts from man­u­fac­tur­ers and phar­ma­cies, it said, adding that about half of com­mer­cial plans saw a fall in per mem­ber drug spend­ing, and a 0.3% de­cline across Medicare plans.

Twen­ty five years ago, the era of block­buster drugs was tak­ing off, char­ac­ter­ized by mid-to-high-dou­ble-dig­it an­nu­al in­creas­es in drug spend­ing, the com­pa­ny said, not­ing that to­day we are in the age of break­through treat­ments with “break-the-bank pric­ing.”

“We ex­pect man­u­fac­tur­ers of high-priced spe­cial­ty drugs, which cur­rent­ly con­sume half of all drug spend­ing, to con­tin­ue to raise prices faster than core in­fla­tion. And we ex­pect the con­tentious pub­lic pol­i­cy de­bate on how to make pre­scrip­tion med­i­cine, and es­pe­cial­ly in­sulin and oth­er bi­o­log­ics, more af­ford­able for the unin­sured and un­der­in­sured to con­tin­ue,” the com­pa­ny said, fore­cast­ing an an­nu­al drug trend of 2% for the next three years.

Da­ta in­creas­ing­ly sug­gest that pric­ing is con­tribut­ing to a small­er slice of bio­phar­ma growth than ever be­fore. In a note pub­lished ear­li­er this week, Leerink’s Ge­of­frey Porges said “pos­i­tive list pric­ing has con­tributed at least two thirds of in­dus­try growth in re­cent years and this con­tri­bu­tion ap­pears to be fad­ing, if not dis­ap­pear­ing…in many strik­ing cas­es we are see­ing sig­nif­i­cant ab­solute re­duc­tions in price, which was pre­vi­ous­ly un­think­able for this in­dus­try.” For ex­am­ple, PC­SK9 an­ti­bod­ies by Am­gen as well as part­ners Sanofi and Re­gen­eron have re­cent­ly seen heavy dis­counts, while CGRP an­ti­bod­ies from Te­va, Lil­ly as well as part­ners Am­gen and No­var­tis have tak­en a large­ly con­ser­v­a­tive ap­proach to pric­ing.

Drug pric­ing has emerged as a bi­par­ti­san is­sue and a host of law­mak­ers, in­clud­ing those rep­re­sent­ing the Trump ad­min­is­tra­tion, have pro­posed a num­ber of so­lu­tions to low­er the bur­den of drug costs on con­sumers.

Slides from Ex­press Scripts re­port

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Ken Frazier, AP Images

Why Mer­ck wait­ed, and what they now bring to the Covid-19 fight

Nicholas Kartsonis had been running clinical infectious disease research at Merck for almost 2 years when, in mid-January, he got a new assignment: searching the pharma giant’s vast libraries for something that could treat the novel coronavirus.

The outbreak was barely two weeks old when Kartsonis and a few dozen others got to work, first in small teams and then in a larger task force that sucked in more and more parts of the sprawling company as Covid-19 infected more and more of the globe. By late February, the group began formally searching for vaccine and antiviral candidates to license. Still, while other companies jumped out to announce their programs and, eventually and sometimes controversially, early glimpses at human data, Merck remained silent. They made only a brief announcement about a data collection partnership in April and mentioned vaguely a vaccine and antiviral search in their April 28 earnings call.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Mark Genovese (Stanford via Twitter)

Gilead woos fil­go­tinib clin­i­cal in­ves­ti­ga­tor from Stan­ford to lead the charge on NASH, in­flam­ma­to­ry dis­eases

With an FDA OK for the use of filgotinib in rheumatoid arthritis expected to drop any day now, Gilead has recruited a new leader from academia to lead its foray into inflammatory diseases.

Mark Genovese — a longtime Stanford professor and most recently the clinical chief in the division of immunology and rheumatology — was the principal investigator in FINCH 2, one of three studies that supported Gilead’s NDA filing. In his new role as SVP, inflammation, he will oversee the clinical development of the entire portfolio.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Stephen Isaacs, Aduro president and CEO (Aduro)

Once a high fly­er, a stag­ger­ing Aduro is auc­tion­ing off most of the pipeline as CEO Stephen Isaacs hands off the shell to new own­ers

After a drumbeat of failure, setbacks and reorganizations over the last few years, Aduro CEO Stephen Isaacs is handing over his largely gutted-out shell of a public company to another biotech company and putting up some questionable assets in a going-out-of-business sale.

Isaacs —who forged a string of high-profile Big Pharma deals along the way — has wrapped a 13-year run at the biotech with one program for kidney disease going to the new owners at Chinook Therapeutics. A host of once-heralded assets like their STING agonist program partnered with Novartis (which dumped their work on ADU-S100 after looking over weak clinical results), the Lilly-allied cGAS-STING inhibitor program and the anti-CD27 program out-licensed to Merck will all be posted for auction under a strategic review process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

Almost two years after first buying into Genor Biopharma’s pipeline of cancer and autoimmune therapies, Hillhouse Capital has led a $160 million cash injection to push the late-stage assets over the finish line while continuing to fund both internal R&D and dealmaking.

The Series B has landed right around the time Genor would have listed on the Hong Kong stock exchange, according to plans reported by Bloomberg late last year. Insiders had said that the company was looking to raise about $200 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Fangliang Zhang (Imaginechina via AP Images)

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Almost exactly three years after Shanghai-based Legend came out of nowhere to steal the show at ASCO with jaw-dropping data on their BCMA-targeted CAR-T for multiple myeloma, the little player with Big Pharma connections is taking a giant step toward making it big on Wall Street. And this time they want to seal the deal on a global rep after staking out a unicorn valuation in what’s turned out to be a bull market for biotech IPOs — in the middle of a pandemic.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Federico Mingozzi (Spark)

Spark touts an­i­mal da­ta for a so­lu­tion to AAV gene ther­a­py's an­ti­body prob­lem

Among all the limitations of using an adeno-associated virus as a vector to deliver a gene — still the most established modality in gene therapy given years of trial and error and finally success — the presence of neutralizing antibodies, whether pre-existing or induced, looms large.

“When I think about the immune responses in AAV, I try to sort of layer them,” Federico Mingozzi, the CSO at Spark Therapeutics, told Endpoints News. “The antibody is the first layer. It’s the first block that you find when you’re trying to do gene transfer.”